This standard is based on NG85.
This standard should be read in conjunction with QS15, QS124 and QS13. NICE has developed guidance and a quality standard on patient experience in adult NHS services (see the NICE Pathway on patient experience in adult NHS services), which should be considered alongside these quality statements. Statements 5 and 10 in the quality standard on patient experience in adult NHS services are particularly relevant in the context of supporting adults with pancreatic cancer.
Quality statements
Other quality standards that should be considered when commissioning or providing pancreatic cancer services include suspected cancer and end of life care for adults.
A full list of NICE quality standards is available from the quality standards topic library.
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Definitions of terms used in this quality statement
Suspected pancreatic cancer Suspected pancreatic cancer Pancreatic cancer is suspected based on findings from a standard CT and/or a pancreatic protocol CT. Pancreatic cysts with high-risk features of pancreatic cancer are included.
[Expert opinion]
Pancreatic cancer (QS177) Quality statement 2: Staging using FDG-PET Quality statement 2: Staging using FDG-PET/CT /CT
Quality statement
Adults with localised pancreatic cancer on CT have staging using fluorodeoxyglucose positron emission tomography/CT (FDG-PET/CT) before they have surgery, radiotherapy or systemic therapy.
Rationale
Undergoing cancer treatment when the pancreatic cancer has already spread can reduce the person's quality of life without increasing their life expectancy. FDG-PET/CT adds information to CT imaging and allows for more accurate staging, particularly with respect to detecting metastatic disease. Confirmation of localised disease ensures that treatment continues as planned, but if the cancer has spread, the treatment can be reviewed based on the new information. This can prevent ineffective surgeries or unnecessary radical local treatments.
Quality measures
Structure Structure
Evidence of local arrangements to ensure that FDG-PET/CT is used for staging in adults with localised pancreatic cancer on CT before they have surgery, radiotherapy or systemic therapy.
Data sour
Data source: ce: Local data collection, for example service protocols.
Process Process
Proportion of adults with localised pancreatic cancer on CT having surgery, radiotherapy or systemic therapy who had FDG-PET/CT before receiving cancer treatment.
Numerator -the number in the denominator who had FDG-PET/CT staging before receiving treatment.
Denominator -the number of adults with localised pancreatic cancer on CT who had surgery, radiotherapy or systemic therapy.
Data sour
Data source: ce: Local data collection, for example patient records. 
Rationale
Prompt resectional surgery has the potential to increase positive outcomes for adults with resectable pancreatic cancer. For those who are well enough for resectional surgery and not enrolled in a clinical trial that requires biliary drainage, performing preoperative biliary drainage can delay surgery, increase complications and hospitalisations, and raise the risk of pre-surgery pancreatitis compared with surgery alone. Carrying out the resection without performing biliary drainage also reduces costs.
Quality measures

Structure Structure
Evidence of local care protocols, which ensure that adults with resectable pancreatic cancer and obstructive jaundice have resectional surgery without preoperative biliary drainage unless the drainage is specifically indicated.
Data sour Data source: ce:
Local data collection, for example service protocols, regional network arrangements, documented local referral policies or agreed patient pathways.
Process Process
Proportion of adults with resectable pancreatic cancer and obstructive jaundice with no indication for preoperative biliary drainage who had resectional surgery without the drainage.
Numerator -the number in the denominator who had resectional surgery without preoperative biliary drainage.
Denominator -the number of adults with resectable pancreatic cancer and obstructive jaundice with no indication for preoperative biliary drainage.
Data sour Data source: ce:
Local data collection, for example patient records. Adults with pancreatic cancer and jaundice Adults with pancreatic cancer and jaundice who are well enough to have an operation to remove their tumour can have the operation without needing to have their jaundice treated first, unless they are in a clinical trial that requires the jaundice to be treated.
Source guidance
Pancreatic cancer in adults: diagnosis and management (2018) NICE guideline NG85, recommendation 1.7.1
Definitions of terms used in this quality statement
Specific indications for biliary dr Specific indications for biliary drainage in adults with resectable pancreatic cancer ainage in adults with resectable pancreatic cancer and obstructiv and obstructive jaundice e jaundice Not being well enough for resectional surgery.
Being enrolled in a clinical trial that requires preoperative biliary drainage.
[NICE's guideline on pancreatic cancer in adults, recommendation 1. 
Quality statement
Adults with unresectable pancreatic cancer are prescribed enteric-coated pancreatin.
Rationale
Pancreatic cancer inhibits the ability of the pancreas to deliver pancreatic enzymes, which assist digestion and absorption of fat, carbohydrates and proteins. Enteric-coated pancreatin can improve the nutritional status and wellbeing of people with pancreatic cancer and, as a result, their ability to tolerate treatment.
Quality measures
Structure Structure a) Evidence of local arrangements to ensure that adults with unresectable pancreatic cancer are prescribed enteric-coated pancreatin.
Data sour
Data source: ce: Local data collection, for example service specification or local protocols.
b) Evidence of local arrangements to ensure that adults with unresectable pancreatic cancer prescribed enteric-coated pancreatin receive advice on how to take it.
Process Process
Proportion of adults with unresectable pancreatic cancer prescribed enteric-coated pancreatin.
Numerator -the number in the denominator prescribed enteric-coated pancreatin.
Denominator -the number of adults with unresectable pancreatic cancer. 
Data sour
What the quality statement means for different audiences
Service pro Service providers viders (secondary and tertiary services, dietetics services and specialist regional centres) ensure that adults with unresectable pancreatic cancer are prescribed enteric-coated pancreatin and given advice on how to use it effectively.
Healthcare professionals Healthcare professionals (such as GPs, dieticians, pancreatic cancer nurse specialists and members of the local cancer network) prescribe enteric-coated pancreatin to adults with unresectable pancreatic cancer and explain how to use it effectively.
Commissioners Commissioners (clinical commissioning groups) ensure that they commission services in which adults with unresectable pancreatic cancer are prescribed enteric-coated pancreatin and given advice on how to use it effectively.
Adults with pancreatic cancer that cannot be treated with surgery Adults with pancreatic cancer that cannot be treated with surgery are given a medicine called pancreatin, which makes it easier to digest food and absorb nutrients. They are given information about how to take the pancreatin tablets to make sure they work as well as possible. Pancreatin can help them to keep their weight stable, feel better, have more energy for normal daily activities and cope with their cancer treatment. 
Source guidance
What is a placeholder statement?
A placeholder statement is an area of care that has been prioritised by the quality standards advisory committee but for which no source guidance is currently available. A placeholder statement indicates the need for evidence-based guidance to be developed in this area.
Rationale
People and their families or carers are often left devastated by a diagnosis of cancer, particularly when they learn that the treatment options are limited and the prognosis is poor. As a result, they often have significant needs for psychological support to help them and their families cope with the diagnosis of a life-limiting disease.
Cancer and cancer treatment can also leave people feeling very unwell. They may experience a range of symptoms that can reduce their quality of life and ability to take part in normal daily activities. Symptoms of pancreatic cancer can include pain, anxiety, depression, fatigue, bowel or digestive problems, loss of appetite, weight loss, itchiness and nausea. People with pancreatic cancer and their families and carers need timely access to information and psychological support to help them cope with these symptoms and side effects, and maintain as good a quality of life as possible for as long as possible. Resource impact NICE quality standards should be achievable by local services. The potential resource impact is considered by the quality standards advisory committee, drawing on resource impact work for the source guidance. Organisations are encouraged to use the resource impact statement and baseline assessment tool for the NICE guideline on pancreatic cancer in adults to help estimate local costs.
Diversity, equality and language
During the development of this quality standard, equality issues were considered and equality assessments are available. Any specific issues identified during development of the quality statements are highlighted in each statement.
Commissioners and providers should aim to achieve the quality standard in their local context, in light of their duties to have due regard to the need to eliminate unlawful discrimination, advance equality of opportunity and foster good relations. Nothing in this quality standard should be interpreted in a way that would be inconsistent with compliance with those duties.
ISBN: 978-1-4731-3210-8
Pancreatic cancer (QS177)
